Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Journal of the American Academy of Dermatology|August 12, 2015
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS studyIan Landells, Colleen Marano, Ming-Chun Hsu, et al.Inflammatory Bowel Diseases|September 23, 2020
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 StudiesWilliam J Sandborn, Brian G Feagan, Silvio Danese, et al.Inflammatory Bowel Diseases|January 7, 2012
Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapyGary Toedter, Katherine Li, Sarah Sague, et al.Journal of Crohn'S & Colitis|June 20, 2018
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance ExtensionWalter Reinisch, Peter R Gibson, William J Sandborn, et al.Journal of Crohn'S & Colitis|February 4, 2024
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative ColitisSubrata Ghosh, Brian G Feagan, Elyssa Ott, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 11, 2022
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI TrialSilvio Danese, Bruce E Sands, Maria T Abreu, et al.Journal of Crohn'S & Colitis|June 20, 2018
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 StudyBruce E Sands, William J Sandborn, Brian G Feagan, et al.Gastroenterology|June 18, 2013
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 10, 2019
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative ColitisOmoniyi J Adedokun, Zhenhua Xu, Colleen Marano, et al.Gastroenterology|June 6, 2013
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.Pageof 3